Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...
The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...